



## **Orchard Therapeutics to Webcast Conference Call of First Quarter 2019 Financial Results on May 28, 2019**

May 22, 2019

BOSTON and LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company will host a conference call and live webcast on Tuesday, May 28, 2019 at 8:00 a.m. ET to report its first quarter 2019 financial results and other business updates.

A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at [orchard-tx.com](http://orchard-tx.com). The conference call can be accessed by dialing 1-866-930-5155 (U.S. domestic) or +1-409-937-8974 (international) and referring to conference ID 2764629. A replay of the webcast will be archived on the Orchard website following the presentation.

### **About Orchard**

Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.

Orchard's portfolio of autologous, *ex vivo*, hematopoietic stem cell gene therapies includes Strimvelis, a gammaretroviral vector based gene therapy and the first such treatment approved by the European Medicines Agency for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID). Additional programs for neurometabolic disorders, primary immune deficiencies and hemoglobinopathies are all based on lentiviral vector based gene modification of autologous HSCs and include three advanced registrational studies for metachromatic leukodystrophy (MLD), ADA-SCID and Wiskott-Aldrich syndrome (WAS), clinical programs for X-linked chronic granulomatous disease (X-CGD) and transfusion-dependent beta-thalassemia (TDT), as well as an extensive preclinical pipeline. Strimvelis, as well as the programs in MLD, WAS and TDT were acquired by Orchard from GSK in April 2018 and originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy initiated in 2010.

Orchard currently has offices in the U.K. and the U.S., including London, San Francisco and Boston.

### **Contacts**

Renee Leck  
Director, Investor Relations  
+1 862-242-0764  
[Renee.Leck@orchard-tx.com](mailto:Renee.Leck@orchard-tx.com)

Source: Orchard Therapeutics plc